A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dasatinib; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 09 Sep 2021 Biomarkers information updated
- 22 Aug 2012 Results of the second phase of this study comparing imatinib 400 mg/day and dasatinib have been published in Blood.
- 09 Jul 2012 Actual patient number is 403 as reported by ClinicalTrilas.gov.